Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Posted by on May 19th, 2026

Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) was the recipient of a large drop in short interest in April. As of April 30th, there was short interest totaling 586,422 shares, a drop of 40.7% from the April 15th total of 988,346 shares. Approximately 5.9% of the shares of the stock are short sold. Based on an average daily volume of 189,024 shares, the days-to-cover ratio is currently 3.1 days.

Institutional Investors Weigh In On Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC acquired a new stake in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned about 0.24% of Cocrystal Pharma as of its most recent filing with the Securities and Exchange Commission. 6.72% of the stock is currently owned by hedge funds and other institutional investors.

Cocrystal Pharma Stock Performance

Shares of NASDAQ COCP opened at $1.18 on Tuesday. The stock has a fifty day moving average price of $1.27 and a two-hundred day moving average price of $1.11. The firm has a market cap of $16.27 million, a P/E ratio of -1.62 and a beta of 1.50. Cocrystal Pharma has a 1 year low of $0.86 and a 1 year high of $2.67.

Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last issued its quarterly earnings results on Thursday, May 21st. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The business had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.23 million. On average, research analysts predict that Cocrystal Pharma will post -0.67 earnings per share for the current fiscal year.

Cocrystal Pharma Company Profile

(Get Free Report)

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.

Featured Articles

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.